Body Composition in Anti-Obesity Medication Trials-Beyond Scales.
作者信息
Agarwal Ank A, Narayan Aditya, Stanford Fatima Cody
机构信息
Stanford University School of Medicine, Palo Alto, California.
Neuroendocrine Unit, Division of Endocrinology, Department of Medicine, Massachusetts General Hospital, Boston.
出版信息
JAMA Intern Med. 2024 Apr 1;184(4):341-342. doi: 10.1001/jamainternmed.2023.7733.
Abstract
摘要
相似文献
1
Body Composition in Anti-Obesity Medication Trials-Beyond Scales.抗肥胖药物试验中的身体成分——超越体重秤测量
JAMA Intern Med. 2024 Apr 1;184(4):341-342. doi: 10.1001/jamainternmed.2023.7733.
2
[The effect of tesofensine on body weight and body composition in obese subjects--secondary publication].[替索芬辛对肥胖受试者体重及身体成分的影响——二次发表]
Ugeskr Laeger. 2009 Oct 5;171(41):2974-7.
3
The safety and efficacy of lorcaserin in the management of obesity.盐酸氯卡色林治疗肥胖症的安全性和有效性。
Postgrad Med. 2013 Nov;125(6):62-72. doi: 10.3810/pgm.2013.11.2713.
4
Long-term pharmacotherapy for obesity and overweight.肥胖和超重的长期药物治疗。
Cochrane Database Syst Rev. 2003(4):CD004094. doi: 10.1002/14651858.CD004094.
5
Long-term pharmacotherapy for obesity and overweight.肥胖和超重的长期药物治疗。
Cochrane Database Syst Rev. 2004;2003(3):CD004094. doi: 10.1002/14651858.CD004094.pub2.
6
The effect of obesity pharmacotherapy on body composition, including muscle mass.肥胖症药物治疗对身体成分（包括肌肉量）的影响。
Int J Obes (Lond). 2025 Mar;49(3):381-387. doi: 10.1038/s41366-024-01533-3. Epub 2024 May 14.
7
Rimonabant for overweight or obesity.利莫那班用于治疗超重或肥胖症。
Cochrane Database Syst Rev. 2006 Oct 18;2006(4):CD006162. doi: 10.1002/14651858.CD006162.pub2.
8
Regular Consumption of Lipigo Promotes the Reduction of Body Weight and Improves the Rebound Effect of Obese People Undergo a Comprehensive Weight Loss Program.常规食用 Lipigo 可促进体重减轻，并改善肥胖人群在综合减肥计划后的反弹效应。
Nutrients. 2020 Jun 30;12(7):1960. doi: 10.3390/nu12071960.
9
Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study.西布曲明对伴有2型糖尿病的肥胖患者的体重减轻和糖尿病控制有效：一项随机、双盲、安慰剂对照研究。
Diabetes Obes Metab. 2000 Apr;2(2):105-12. doi: 10.1046/j.1463-1326.2000.00071.x.
10
Effectiveness and persistence of anti-obesity medications (liraglutide 3 mg, lorcaserin, and orlistat) in a real-world primary care setting.在真实世界的基层医疗环境中，抗肥胖药物（利拉鲁肽 3mg、lorcaserin 和奥利司他）的疗效和持久性。
Fam Pract. 2023 Dec 22;40(5-6):629-637. doi: 10.1093/fampra/cmac141.
引用本文的文献
1
Resistance Exercise in Treating Heart Failure with Preserved Ejection Fraction (HFpEF) and Obesity: Targeting Skeletal Muscle Abnormalities and Ectopic Adipose Depots.阻力运动治疗射血分数保留的心力衰竭（HFpEF）与肥胖：针对骨骼肌异常和异位脂肪堆积
Physiologia. 2025 Mar;5(1). doi: 10.3390/physiologia5010010. Epub 2025 Feb 27.
2
Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight.在针对肥胖或超重成人的SURMOUNT-1研究中，使用替尔泊肽进行体重减轻期间身体成分发生变化。
Diabetes Obes Metab. 2025 May;27(5):2720-2729. doi: 10.1111/dom.16275. Epub 2025 Feb 25.
3
Mitigating muscle loss during weight loss: can nutritional ketosis make a difference? A call for more research.减轻减肥期间的肌肉流失：营养性生酮能起作用吗？呼吁开展更多研究。
Obesity (Silver Spring). 2025 Mar;33(3):431-434. doi: 10.1002/oby.24235. Epub 2025 Feb 13.
4
Nutritional and functional outcomes in trials of nutrient-stimulated hormone-based therapy-A systematic mapping review.基于营养素刺激激素疗法试验中的营养与功能结局——一项系统图谱综述
Obes Rev. 2025 May;26(5):e13890. doi: 10.1111/obr.13890. Epub 2025 Jan 27.
5
Fundamental Body Composition Principles Provide Context for Fat-Free and Skeletal Muscle Loss With GLP-1 RA Treatments.基础身体成分原理为GLP-1受体激动剂治疗导致的无脂肪和骨骼肌流失提供了背景信息。
J Endocr Soc. 2024 Sep 25;8(11):bvae164. doi: 10.1210/jendso/bvae164. eCollection 2024 Sep 26.
6
The Patient's Journey in Obesity within the United States: An Exercise of Resilience against Disease.美国肥胖患者的历程：一场对抗疾病的韧性考验。
Life (Basel). 2024 Aug 27;14(9):1073. doi: 10.3390/life14091073.
7
A new framework for the diagnosis, staging and management of obesity in adults.成人肥胖症诊断、分期及管理的新框架。
Nat Med. 2024 Sep;30(9):2395-2399. doi: 10.1038/s41591-024-03095-3.
8
Challenges With Relying on Body Fat and Weight Values for Obesity-Reply.依靠身体脂肪和体重值诊断肥胖的挑战——回复
JAMA Intern Med. 2024 Aug 1;184(8):990-991. doi: 10.1001/jamainternmed.2024.2376.
本文引用的文献
1
Equity and Obesity Treatment - Expanding Medicaid-Covered Interventions.公平与肥胖症治疗——扩大医疗补助覆盖的干预措施
N Engl J Med. 2023 Jun 22;388(25):2309-2311. doi: 10.1056/NEJMp2303268. Epub 2023 Jun 17.
2
The Challenge of Defining the Optimal Lifestyle Weight Loss Intervention for Real-world Settings.为现实环境定义最佳生活方式减肥干预措施的挑战。
JAMA. 2022 Dec 13;328(22):2213-2214. doi: 10.1001/jama.2022.21908.
3
A call for solutions for healthy aging through a systems-based, equitable approach to obesity.呼吁通过基于系统的、公平的肥胖症应对方法来寻找健康老龄化的解决方案。
J Am Geriatr Soc. 2022 May;70(5):1599-1604. doi: 10.1111/jgs.17732. Epub 2022 Mar 9.
4
Body composition, dual-energy X-ray absorptiometry and obesity: the paradigm of fat (re)distribution.身体成分、双能X线吸收测定法与肥胖：脂肪（再）分布范例
BJR Case Rep. 2019 Mar 14;5(3):20170078. doi: 10.1259/bjrcr.20170078. eCollection 2019 Sep.
5
Obesity Pathogenesis: An Endocrine Society Scientific Statement.肥胖症发病机制：内分泌学会科学声明。
Endocr Rev. 2017 Aug 1;38(4):267-296. doi: 10.1210/er.2017-00111.
Zotero 插件